{"organizations": [], "uuid": "e361ca1a9168045572b8feb3caf7987210a581df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merck-kgaa-to-develop-abituzumab-i/brief-merck-kgaa-to-develop-abituzumab-in-metastatic-colorectal-cancer-with-sfj-pharmaceuticals-idUSFWN1S90LV", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T15:21:00.000+03:00", "replies_count": 0, "uuid": "e361ca1a9168045572b8feb3caf7987210a581df"}, "author": "", "url": "https://www.reuters.com/article/brief-merck-kgaa-to-develop-abituzumab-i/brief-merck-kgaa-to-develop-abituzumab-in-metastatic-colorectal-cancer-with-sfj-pharmaceuticals-idUSFWN1S90LV", "ord_in_thread": 0, "title": "BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [{"name": "germany", "sentiment": "none"}, {"name": "darmstadt", "sentiment": "none"}], "organizations": [{"name": "mcrc", "sentiment": "none"}, {"name": "merck kgaa", "sentiment": "none"}, {"name": "merck kgaa", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sfj pharmaceuticals reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 12:23 PM / in 14 minutes BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals Reuters Staff\nMay 2 (Reuters) - Merck KGaA:\n* MERCK KGAA, DARMSTADT, GERMANY TO DEVELOP ABITUZUMAB IN METASTATIC COLORECTAL CANCER WITH SFJ PHARMACEUTICALS GROUP\n* MERCK KGAA - SFJ PHARMACEUTICALS GROUP TO DEVELOP ABITUZUMAB AS FIRST-LINE TREATMENT FOR MCRC IN COMBINATION WITH ERBITUX AND CHEMOTHERAPY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T15:21:00.000+03:00", "crawled": "2018-05-02T15:43:40.023+03:00", "highlightTitle": ""}